Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367306 | 1.00 | CACNA2D1 (0.45) | CACNA2D1SLC6A2SLC7A5SLC6A9ALDH1A1 | |
| SCHEMBL22367335 | 0.89 | CACNA2D1 (0.38) | CACNA2D1SLC6A2SLC7A5SLC6A9 | |
| SCHEMBL22367340 | 0.89 | CACNA2D1 (0.38) | CACNA2D1SLC6A2SLC7A5SLC6A9 | |
| SCHEMBL19553104 | 0.86 | CACNA2D1 (0.42) | CACNA2D1SLC6A2SLC7A5SLC6A9 | |
| SCHEMBL19553106 | 0.86 | CACNA2D1 (0.42) | CACNA2D1SLC6A2SLC7A5SLC6A9 | |
| SCHEMBL22457002 | 0.85 | CACNA2D1 (0.41) | CACNA2D1SLC6A2SLC7A5SLC6A9ALDH1A1 | |
| SCHEMBL29967278 | 0.85 | CACNA2D1 (0.41) | CACNA2D1SLC6A2SLC7A5SLC6A9ALDH1A1 | |
| SCHEMBL22367423 | 0.82 | CACNA2D1 (0.39) | CACNA2D1SLC6A2SLC7A5CYP2D6CYP2C9 | |
| SCHEMBL22367427 | 0.82 | CACNA2D1 (0.39) | CACNA2D1SLC6A2SLC7A5CYP2D6CYP2C9 | |
| SCHEMBL19553331 | 0.81 | SLC7A5 (0.41) | CACNA2D1SLC6A2SLC7A5SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | CACNA2D1 10/4885SLC6A2 28/4885SLC7A5 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.